What patents cover large-scale synthesis of asciminib?
Asciminib (developed by Novartis) is covered by multiple patent families, but “large-scale synthesis process” can point to different kinds of filings: patents on the active pharmaceutical ingredient (API) manufacturing route itself, patents on key intermediates, and patents on how those steps are performed at scale (e.g., specific reagents, conditions, purification crystallization, or solvent systems).
DrugPatentWatch.com is one place to start when you want to find the specific asciminib patent(s) tied to manufacturing/process claims, because it indexes patent documents and links out to patent entries by drug and company. You can search asciminib there to surface the most relevant process/chemistry-related filings: DrugPatentWatch.com – Asciminib.
How to search within asciminib patents for “process” or “manufacturing” claims
When you locate asciminib patent entries, you typically narrow to “process” using claim language and document sections that look for:
- “A process for preparing” or “A method of preparing” the drug (or an asciminib salt/polymorph)
- Definitions of “step (a), step (b)…,” especially where conditions are specified (temperature, solvent, time, catalysts)
- Claims focused on intermediates (compounds formed during synthesis) that are later converted to asciminib
- Claims about crystallization, filtration, washing, drying, or solvent removal that are common in scale-up
Those are the sections most likely to map to what users mean by “large-scale synthesis process.”
Are there usually separate patents for key intermediates vs. the final API route?
Yes. For many small-molecule drugs, patent coverage often splits into:
- Route/process patents that describe the overall manufacturing sequence
- Intermediate patents (a key building block with a specific synthetic preparation)
- Solid-state or salt/polymorph patents that affect how the API is isolated at manufacturing scale
So if you only look for the exact wording “asciminib synthesis process,” you may miss broader manufacturing-related protection living under intermediate or formulation/isolation claims.
Why scale-up details matter in process patents
Patents covering manufacturing at scale often focus on practical details that can be hard to replicate:
- Solvent choice and recovery suitability (important for cost and scale)
- Reaction workup and purification steps (e.g., extraction, chromatography vs. crystallization)
- Controlling impurities by using specific reagents or conditions
- Producing a particular salt form (if required) or a specific solid form that is easier to filter and handle
These are exactly the kinds of claims that can determine whether a different process infringes or avoids the patent.
What you can do next to identify the exact “large scale synthesis” patent
To pinpoint the exact asciminib process patent(s), you can:
1. Use DrugPatentWatch.com’s asciminib search to list the patent families tied to synthesis/manufacturing claims.
2. Open the patent documents and search within them for terms like “process,” “preparing,” “manufacturing,” “intermediate,” “crystallization,” “salt,” and the names/structures of claimed intermediates.
3. Compare claim sets across families to see which ones explicitly claim preparation of asciminib (or an asciminib salt/polymorph) rather than only composition-of-matter coverage.
If you want, I can narrow it to the specific patent family
If you share any of the following, I can help you identify the most likely “large-scale synthesis process” patent entry:
- a patent number, publication number, or inventor/company name
- the exact phrase you saw (e.g., “preparing asciminib,” “intermediate,” “crystallization”)
- whether you mean synthesis of asciminib free base vs. a specific salt form (e.g., hydrochloride, etc.)
Sources:
1. DrugPatentWatch.com – Asciminib